Skip to Content
Merck

SML0248

Zolmitriptan

≥98% (HPLC)

Synonym(s):

(4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone, (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone, 311C90

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H21N3O2
CAS Number:
139264-17-8
Molecular Weight:
287.36
NACRES:
NA.77
PubChem Substance ID:
329825258
UNSPSC Code:
12352200
MDL number:
MFCD00871503

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Zolmitriptan, ≥98% (HPLC)

InChI

1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

SMILES string

CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12

InChI key

ULSDMUVEXKOYBU-ZDUSSCGKSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -3 to -8°, c = 1 in methanol

color

white to beige

solubility

DMSO: ≥5 mg/mL

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... HTR1B(3351), HTR1D(3352)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Zolmitriptan has been used as a 5-hydroxytryptamine receptor 1B (5-HT1B/D) activator to treat grafts to study its effects on the morphology of the ectopic eye.
Zolmitriptan has been used to induce hyper-innervation of transplants.

Biochem/physiol Actions

Zolmitriptan is a potent, selective. centrally and peripherally acting 5HT1B/1D receptor agonist.
Zolmitriptan is a selective serotonin receptor agonist of the 5HT1B and 5HT1D subtypes, both centrally and peripherally. It has been used clinically for the acute treatment of migraine attacks with or without aura and cluster headaches.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000480091
0000480091
0000225378
0000225378
0000137099

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Rolan
Cephalalgia : an international journal of headache, 17 Suppl 18, 21-27 (1997-12-17)
Seven randomized studies in healthy volunteers have investigated interactions between zolmitriptan (Zomig, formerly 311C90), a 5HT1B/1D agonist for acute migraine therapy, and selected drugs with which there was a possibility of interaction or a likelihood of concurrent use. Co-administration of
G R Martin
Cephalalgia : an international journal of headache, 17 Suppl 18, 4-14 (1997-12-17)
Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The drug differs from presently available members of this drug class in that it combines
R B Lipton et al.
Cephalalgia : an international journal of headache, 17 Suppl 18, 53-59 (1997-12-17)
Zolmitriptan (Zomig, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological
Peter J Goadsby et al.
Headache, 46(1), 138-149 (2006-01-18)
Migraine is a common disabling neurological disorder, associated with headache, nausea, and on occasions vomiting. Zolmitriptan is a widely available serotonin 5HT(1B/1D) receptor agonist with a long track record in clinical studies and in the treatment of acute migraine. A
David W Dodick et al.
Cephalalgia : an international journal of headache, 31(3), 296-300 (2010-10-13)
Endpoints used to evaluate the efficacy of acute anti-migraine drugs do not measure the tolerability. Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire. The
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service